$heff's $tation of $tocks & $olid DD

[BiotechValues]

$RMTI- back in my buy range now.

Q4 a mixed bag- but many positives, including strong balance sheet/no debt.


"We had a very eventful active year," stated Mr. Robert L. Chioini, Chairman and Chief Executive Officer of Rockwell. "Our fourth quarter was exceptional and included three major milestone accomplishments. First, we monetized and de-risked our operating business and positioned it for future growth through our new partnership with Baxter. Then, we conducted a successful FDA advisory committee meeting, achieving a majority vote to approve Triferic as the only iron replacement and hemoglobin maintenance drug for hemodialysis patients. Additionally, we completed a successful financing, strengthening our cash and liquidity position resulting in a strong balance sheet with no debt."



http://finance.yahoo.com/news/rockwell-medical-reports-fourth-quarter-210100140.html